TOKYO, JAPAN – SBC Medical Group Holdings Inc. (SBC:NASDAQ) reported steady financial growth for Q3 2024, with revenues for the first nine months rising 23% to $160 million. This growth stemmed from increased clinic franchise fees and expansion. Despite higher operating expenses from consulting, stock-based compensation, and office costs, nine-month EBITDA increased 22% to $68.4 million. However, quarterly EBITDA declined 36% to $14.8 million due to costs from its public listing.
Cash Flow and Liquidity
With cash reserves of $137.4 million, SBC Medical strengthened liquidity through robust operational cash flows. Operating cash flow rose 23%, driven by net income growth and effective receivables collection, while financing inflows from reverse recapitalization boosted cash flow. The company remains focused on strategic investments and self-sustained growth.
Corporate Overview
Based in Irvine, California, and Tokyo, Japan, SBC Medical supports cosmetic treatment franchises with services like marketing, recruitment, facility design, and IT solutions. The company licenses technology and trademarks, enhancing franchisee operations with comprehensive support tools and loyalty programs.
